Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥7,800 JPY
Change Today -135.00 / -1.70%
Volume 5.8M
As of 2:00 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Haruo Naito

Chief Executive Officer, Representative Corporate Officer and Director, Eisai Co., Ltd.
AgeTotal Calculated CompensationThis person is connected to 11 board members in 1 different organizations across 4 different industries.

See Board Relationships
--¥129,000,000
As of Fiscal Year 2014

Background*

Mr. Haruo Naito has been Chief Executive Officer of Eisai Co. Ltd. at Eisai, Inc. since June 2003 and has been its Representative Corporate Officer since June 2004. Mr. Naito has been President of Genox Research, Inc. since March 1996 and Drug Delivery System Institute, Ltd. since June 2003. He joined Eisai Co. Ltd. in October 1975 and became its Managing Director in June 1985; Representative Director and Senior Managing Director in June 1986; and Deputy President in ...

Read Full Background

Corporate Headquarters*

4-6-10, Koishikawa
Tokyo, -- 112-8088

Japan

Phone: 81 3 3817 3700
Fax: --

Board Members Memberships*

1983-Present
Chief Executive Officer, Representative Corporate Officer and Director

Education*

There is no Education data available.

Other Affiliations*

Annual Compensation*

Salary¥94,000,000
Bonus¥21,000,000
Total Annual Compensation¥115,000,000

Stock Options*

Restricted Stock Awards¥10,000,000

Total Compensation*

Total Annual Cash Compensation¥115,000,000
Total Short Term Compensation¥115,000,000
Other Long Term Compensation¥10,000,000
Total Calculated Compensation¥129,000,000
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥7,800.00 JPY -135.00

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$557.2K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$860.0K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Eduardo Javier Sanchiz Yrazu Chief Executive Officer, Chief Executive of Corporate Development & Finance, Executive Director, Member of Management Board and Member of Compliance Committee
Almirall, S.A.
--
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.